Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.55 |
| ▸ | MEN1 | O00255 | 8/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2919939 | 0.90 | KMT2A (0.48) | KMT2AMEN1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2915259 | 0.89 | KMT2A (0.55) | KMT2AMEN1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2909645 | 0.88 | KMT2A (0.53) | KMT2AMEN1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL13956772 | 0.83 | KMT2A (0.59) | KMT2AMEN1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4540503 | 0.82 | KMT2A (0.56) | KMT2AMEN1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2916577 | 0.82 | ALDH1A1 (0.58) | KMT2AMEN1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4361550 | 0.81 | MEN1 (0.65) | KMT2AMEN1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4363853 | 0.81 | ALDH1A1 (0.57) | KMT2AMEN1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL13956758 | 0.79 | MEN1 (0.62) | KMT2AMEN1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL13956767 | 0.79 | MEN1 (0.57) | KMT2AMEN1RAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | claimed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | claimed |
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | claimed |
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | NAT1, PIGS, ADORA1 | KMT2A 1884/4885MEN1 4556/4885RAB9A 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.